When was Neurofold Therapeutics founded?

Neurofold Therapeutics was founded in 2024 and raised its 1st funding round 2 years after it was founded.

Where is Neurofold Therapeutics located?

Neurofold Therapeutics is headquartered in Greenwood Village, United States.

Is Neurofold Therapeutics a funded company?

Neurofold Therapeutics is a funded company, having raised a total of $***** in its 1st and only funding round, a Series A round on Jun 25, 2026.

When was the latest funding round of Neurofold Therapeutics?

Neurofold Therapeutics' latest funding was a $***** Series A round on Jun 25, 2026, with participation from 0 investor. Its primary sector is Diversified Pharmaceuticals. In United States, the Diversified Pharmaceuticals sector has seen $710M in funding in 2026 to date.

Where does Neurofold Therapeutics rank among its competitors?

Neurofold Therapeutics ranks 696th amongst 2099 active competitors, of which 114 are funded. It stands 2nd in terms of total funding among its competitors. The most recent competitor to raise funding was Neurofold Therapeutics, which secured $6.5M in Jun, 2026.

Who are the top competitors of Neurofold Therapeutics?

Neurofold Therapeutics' top competitors include AbbVie, Merck and Gilead. Among them, Neurofold Therapeutics secured the most recent funding round in June, 2026.

Neurofold Therapeutics - 2026 Company Profile, Funding & Competitors

Neurofold Therapeutics is a series A company based in Greenwood Village (United States), founded in 2024. It operates as a Developer of small-molecule therapeutics designed to combat neurodegenerative diseases. Neurofold Therapeutics has raised $6.5M in funding. The company has 2099 active competitors, including 114 funded and 219 that have exited. Its top competitors include companies like AbbVie, Merck and Gilead.

Company Details

Developer of small-molecule therapeutics designed to combat neurodegenerative diseases. Its technology utilizes a proprietary platform to generate synthetic protein mimetics that combine the brain bioavailability of small molecules with the binding specificity of antibody therapies, enabling pharmaceutical researchers to access disease-modifying treatments that reduce neurotoxic protein aggregates and rescue disease phenotypes in preclinical models.

Key Metrics

Founded Year

2024

Location

Greenwood Village, United States

Stage

Series A

Total Funding

$6.5M in 1 round

Latest Funding Round

Series A, Jun 25, 2026, $*****

Ranked

696^th among 2099 active competitors

Similar Companies

AbbVie & 2129 more

View Neurofold Therapeutics' full profile

Neurofold Therapeutics has raised a total funding of $6.5M over 1 round.

Here is the list of recent funding rounds of Neurofold Therapeutics:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Jun 25, 2026	4728763	Series A	7329122	4983886	4118688	5192731

Access funding benchmarks and valuations. Sign up today!

View details of Neurofold Therapeutics's funding rounds and investors

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Neurofold Therapeutics include AbbVie, Merck and Gilead. Here is the list of Top 10 competitors of Neurofold Therapeutics, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	AbbVie 2012, Chicago (United States), Public	Research-based biopharmaceutical company	$14.7B	Berkshire Hathaway, Alcor Fund & 10 others	84/100
2nd	Merck 1891, Rahway (United States), Public	Manufacturer of pharmaceutical products	-	Bill & Melinda Gates Foundation, Berkshire Hathaway ... & 11 others	83/100
3rd	Gilead 1987, Foster City (United States), Acquired	Developer of medicines to treat HIV/AIDS, liver diseases, cancer & others	-	BB Biotech, Jindal Ventures & 18 others	82/100
4th	Amgen 1980, Thousand Oaks (United States), Public	Developer of pharmaceutical products for treating multiple diseases	-	Digital Pharma Lab, Amgen Business Development ... & 11 others	80/100
5th	AstraZeneca 1999, Cambridge (United Kingdom), Public	Developer of pharmaceutical medicines for oncology and various chronic diseases	-	Digital Pharma Lab, Columbia Capital & 13 others	77/100
6th	Lilly 1876, Indianapolis (United States), Public	Developer of traditional pharmaceutical medicines	-	Alcor Fund, Digital Pharma Lab & 11 others	76/100
7th	Johnson & Johnson 1886, New Brunswick (United States), Public	Manufacturer and supplier of beauty care products, medical devices, and pharmaceutical products	-	Western Technology Investment, Alcor Fund ... & 17 others	76/100
8th	Novartis 1996, Basel (Switzerland), Acquired	R&D focused on manufacturing of drugs for multiple therapeutic areas	-	Digital Pharma Lab, Atlas Venture & 9 others	72/100
9th	Roche 1896, Basel (Switzerland), Public	Developer of pharmaceuticals and diagnostics kits	-	Gilde Healthcare, SoftBank Group & 12 others	71/100
10th	Pfizer 1849, New York City (United States), Public	Provider of pharmaceutical products for multiple disease treatments	-	Berkshire Hathaway, Alcor Fund & 16 others	71/100
696th	Neurofold Therapeutics 2024, Greenwood Village (United States), Series A	Developer of small-molecule therapeutics designed to combat neurodegenerative diseases	$6.5M	-	22/100